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Abstract A gizzard cDNA library was screened by the two- 
hybrid system using as bait the 6 lsoform of the catalytic subunit 
of protein phosphatase 1 (PP16). Among the proteins identified 
was a fragment of the polypyrimidine tract-binding protein- 
associated splicing factor (PSF) and for 242 residues was 97.1% 
identical to the human isoforms. Binding of PSF and PP16 was 
confwmed by inhibition of phosphatase activity and by an overlay 
technique. The PP16 binding site was contained in the N- 
terminal 82 residues of the PSF fragment. PSF may therefore 
act as a PPl target molecule in the spliceosome. 
Kt y words: Protein phosphatase type 1; 
T\vo-hybrid system; Human splicing factor PSF 
1. Introduction 
The formation of mRNA from its precursor, pre-mRNA, 
in\-olves the removal of introns. This reaction occurs in the 
nucleus within a dedicated, high-molecular mass assembly, 
termed the spliceosome [1,2]. This assembly involves small 
nuclear ribonucleoprotein particles (snRNPs) and other splic- 
ins: factors [3]. The spliceosomes assemble on pre-mRNA as 
discrete complexes and four functional intermediates have 
bezn identified, i.e. E + A + B + C [2,3]. The products of the 
initial catalytic step (exon 1 and lariat-exon 2) are associated 
with the C complex. The exons are then rapidly ligated in the 
second catalytic step and released from the C complex. After 
thi, binding of Ul snRNP to pre-mRNA the subsequent 
evc:nts required ATP [l] and it is likely that phosphorylation 
reactions are involved. Several lines of evidence support this 
as\umption, including the use of ATP analogs [4], application 
of phosphatase inhibitors [ti] and purified phosphatases 
[S.!i], and the phosphorylation of several spliceosome compo- 
nents, notably those containing the RS-rich domain [7-91. In 
getleral, details of the phosphorylation-dependent mechanisms 
an not known. With respect to the phosphatases involved the 
specific substrates are not identified and there is no informa- 
ticIn on phosphatase-binding, or target, molecules. 
The concept that such target molecules may regulate phos- 
phltase activity is based on their ability to bind to the cata- 
lytic subunit and to the substrate, the classical example being 
th‘it of the G-subunit involved in glycogen metabolism [lo]. 
T(l search for potential target molecules in smooth muscle, the 
twg)-hybrid system [l l] was applied using the 6 isoform of the 
catalytic subunit of type 1 phosphatase (PP16) as bait to 
screen a chicken gizzard cDNA library [12]. One of the inter- 
acting proteins identified was a splicing factor, the polypyri- 
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midine tract-binding protein-associated splicing factor, termed 
PSF [13]. This binds to the polypyrimidine tract of mamma- 
lian introns [14] and was suggested to be essential for the 
second catalytic step occurring on the short-lived C complex 
[IS]. This study documents the interaction of PSF and PPI 
and suggests that PSF could act as a target molecule in the 
spliceosome. 
2. Materials and methods 
2.1. Two hybrid screening 
This system was established [12] using PP16 to screen a chicken 
gizzard cDNA library. The library plasmid for clone 24 was recovered 
and examined for interaction with various bait constructs, i.e. pASl- 
PP16 (nomal bait) and two control constructs to screen for false 
positives [12]. Yl90 cells were transformed with these plasmids alone 
or with these bait plus pGAD424-clone 24 and assayed for P-galacto- 
sidase activity [16]. Only the pASl-PPlG plus pGAD424-clone 24 pair 
gave measurable activity. 
2.2. Expression of the PSFfragment 
The fragment of chicken PSF (crPSF fragment) was expressed as a 
hexahistidine-tagged protein in the pQE E. coli system (Qiagen). The 
clone 24 insert was amplified by PCR using primers designed to in- 
troduce BamHI and PstI sites. The BamHI and PstI-digested insert 
was ligated with vector, pQE 32. The nucleotide sequence of this 
construct was determined and was identical to the pGAD424-clone 
24. It encoded a 237 residue fragment (residues K349 through M585 
of human PSF) plus the hexahistidine tag (MRGSHHHHHHGIP) at 
the N-terminus and an 8 residue peptide at the C-terminus 
(DLQPSLIS). Both additional peptides were derived from the vector. 
Expression and purification of crPSF fragment were as described pre- 
viously for recombinant PPlS [12]. 
2.3. Cleavage of the PSFfragment 
Cleavage at the single C residue, corresponding to residue 431 of 
human PSF [13] was achieved with the 5,5’-dithiobis(2-nitrobenzoic 
acid)-CN complex (DTNB-CN) as described [17]. After cleavage the 
mixture was dialyzed against 20 mM Tris-HCI (pH 8.0) and 0.1 M 
KCl, clarified by centrifugation at 25 OOOXg for 15 min, and the 
supernatant applied to a Ni-agarose column and washed with dialysis 
buffer. The C-terminal peptide was recovered in the flow through and 
the bound protein (N-terminal peptide plus uncleaved molecule) 
eluted with 0.25 M imidazole-HCl (pH 8.0) in dialysis buffer. This 
fraction contained a molar ratio of N-terminal peptide to parent mo- 
lecule of 11: 1. Further purification of the N-terminal peptide was 
hindered by the tendency of the peptide to aggregate at lower ionic 
strengths. 
2.4. Expression of full-length recombinant PSF 
The full-length human PSF was expressed as a hexahistidine-tagged 
protein as described earlier [13]. The initial stages of purification fol- 
lowed the previous protocol [12] but after elution from the metal 
affinity column (Talon, Clontech) the procedure was modified. The 
bound protein was eluted by 0.1 M imidazole, 20 mM Tris-HCl (pH 
8.0) 0.1 M NaCl and 6 M guanidine-HCl. When the column eluate 
was dialyzed directly to remove guanidine, most of the hrPSF preci- 
pitated. Therefore, the column eluate was first rapidly diluted with 50 
~01s. of 20 mM Tris-HCI (pH 8.0), 1 M NaCl, 0.05% Tween 20, 5 mM 
dithiothreitol, 25 &ml leupeptin, 0.5 mM diisopropyl fluoropho- 
sphate and then dialyzed against 20 mM Tris-HCl (pH 8.0), 0.1 M 
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KCl, 0.2 mM EDTA, 0.03% Brij 35, 0.5 mM dithiothreitol. Using this 
procedure, most of the hrPSF remained soluble. The dialysate was 
concentrated by centriprep-30 and microcon- concentrators (Ami- 
con). The purity was about 60%. The concentration of hrPSF was 
estimated on SDS-PAGE after staining with Coomassie brilliant 
blue R-250 (Sigma) with bovine serum albumin as standard. 
2.5. Other procedures 
The recombinant PPl6 (rPPl8) was expressed as described [12]. The 
catalytic subunit of PP2A (PP2Ac) was isolated from bovine heart 
[18]. An N-terminal fragment of the large phosphatase subunit 
(rN130) was prepared as described [19]. Other protein preparations 
and routine procedures were as listed previously [12]. Phosphatase 
activity was assayed using 32P-labelled 20 kDa light chain [12] and 
conditions are given in the figure legends. Thrombin digestion of rPSF 
in 20 mM Tris-HCl (pH 7.5), 2 mM dithiothreitol was carried out at 
25°C with thrombin (Sigma, 120 U thrombin/mg rPSF) for 2 h. The 
reaction was stopped by addition of 4-amidinophenylmethanesulfonyl 
fluoride to 0.75 mM. The hydrolysis products were separated on the 
Ni-agarose column as described above for DTNB-CN cleavage. For 
the PPlc overlay assay proteins were transferred [12] onto polyviny- 
lidene difluoride membrane (Immobilon-P, Millipore), blocked with 
5% nonfat dry milk in 0.05% Tween 20, 20 mM Tris-HCl (PH 7.4) 
and 0.15 M NaCl for 3 h and incubated for 12 h at 4°C with 3.7 pM 
rPPlG in 2% nonfat dry milk, 0.03% Brij 35, 20 mM Tris-HCl (pH 
7.4) 0.1 M KCI, 0.2 mM EDTA, 1 mM MnC12, and 0.5 mM dithio- 
threitol. The bound PPl6 was detected using a rabbit polyclonal PPl6 
antibody [20] and horseradish peroxidase-conjugated anti-rabbit IgG 
antibody (Sigma). 
3. Results and discussion 
3.1. Two-hybrid screening 
PP16 was used as bait to screen a gizzard cDNA library. 
1 GAATTCGGCACGAGCGCAAAGGCRGAACTGGACGACACCCCCATGCGGGGCCGACAGCTC 
348 AKAELDDTPMRGRQL 
61 CGTGTTCGGTTTGCAACGCACGCTGCCGCGCTGTCAGTGCGT~CCTTTCGCCTTACGTG 
363R"RFATHAAALS"RNLS P Y v 
121 TCCAACGAGTTACTGGAGGAOGCTTTCTTTCTCC~GTTCGGTCC~TGGAGAGAGCTGTTGTG 
383SNELLEEAFSQFGPVERA"" 
I 
181 ATTGTAGATGATCGAGGTAGATCAACAGGCATTGGCCA 
403IVDDRGRSTGKGIVEFASKP 
241 GCTGCCAGAAAAGCGTTTGCGGTGTACTGAGGGAGTGTTCTTGTTGAC~CCACTCCT 
423AARKAFERCTEGVFLLTTTP 
s 
301 AGGCCAGTTATTGTGGAACCTTTGGAGCAACTGGATGATG 
443RPVIVEPLEaLDDEDGLPEK 
361 CTTGCTCAGAAGAACCCGATGTATC-GG-GAG-CTCCTCCCCGTTTTGCTCAG 
463LAQKNPMYaKERETPPRFAQ 
421 CCTGGCAGTTTTGAGTTTGAGTATTCCCAGAGATGGAAAT 
483PGSFEFEYSQRWKSLDEMEK 
H T Y 
481 CAACAGAGAGRACAAGTGGC CATGAAAGATGCCAAGGACAAACTTGAGAGTGAG 
503QQREQ"AKNMKDAKDKLESE 
E 
541 ATGGAAGATGCTTATCATGAGCATCAGGCAAACCTTTTTGCGTC~GACCTTATGAGGCGT 
523MEDAYHEHQANLLRQDLMRR 
601 CAGGAGGAACTGAGACGTATGGAAGAACTCCATAATCAAA 
543~EELRRMEELHNQEMa~RKE 
661 ATTCAGCTCAGGCAGGAGGAGGAGCGTCGCAGACGGGAGG 
5631QLRQEEERRRREEEMMIRQ 
M 
721 CGAG-TGGAAGAACAGAT 
583R E M E E Q M 
Fig. 1. Nucleotide sequence and derived amino acid sequence of 
clone 24. The nucleotide sequence of clone 24 is shown from the 5’- 
ligation site (EcoRI). The amino acid sequence was deduced in- 
frame continuing from the GAL4 activation domain. Underlined se- 
quences are adaptor sequences. The numbering of residues in clone 
24 corresponds to the sequence of human PSF [13]. In the human 
PSF sequence 7 residues arc different. These are shown below the 
clone 24 sequence. 
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Fig. 2. Effect of the recombinant cPSF fragment on phosphatase ac- 
tivity. (A) Assays carried out minus Co2+; (B) assays carried out 
plus Co*+ (0.3 mM CoCle). Other assay conditions: 50 mM Tris- 
HCl (pH 7.4), 0.1 mM EDTA, 0.1 mg/ml bovine serum albumin, 15 
mM KCl, 5 FM 32P-labeled gizzard LC 20, varying crPSF fragment. 
Gizzard PPlc (0); rPPl8 (m); bovine PP2Ac (0); rabbit skeletal 
muscle PPlc (A); myosin-bound phosphatase (A). Data are means 
f S.E.M. (n not less than 3). 
Several proteins were detected [12], including clone 24. The 
nucleotide and derived amino acid sequence of clone 24 is 
shown in Fig. 1 and is compared to a partial sequence (resi- 
dues 348-589) of human PSF [13]. For the 242 residues, 235 
were identical (97.1% identity). The nucleotide sequence iden- 
tity over this region was 81%. It is concluded, therefore, that 
clone 24 encodes part of the chicken PSF molecule and will be 
referred to as ‘cPSF fragment’. The cPSF fragment is predo- 
minantly hydrophilic and more acidic (theoretical pZ= 5.5) 
than the parent human molecule (theoretical pZ= 10.3). 
3.2. Inhibition of phosphatase activity by crPSF fragment 
To obtain an independent criterion for the interaction of 
PP16 and the PSF fragment, the effect of crPSF fragment on 
phosphatase activity was determined. In the absence of Co’+ 
the crPSF fragment inhibited PPlc from turkey gizzard and 
rPPl8 (Fig. 2A). Half-maximal inhibition was at about 1 pM 
crPSF fragment. In contrast, PP2Ac was not inhibited at con- 
centrations up to 30 pM. In the presence of 0.3 mM CoCls 
(Fig. 2B) PPlc from gizzard (predominantly 35 kDa species) 
and rabbit skeletal muscle (predominantly 38 kDa species) 
were inhibited similarly (half-maximal inhibition at about 
3 pM). Inhibition of rPP18 by crPSF showed half-maximal 
inhibition at about 0.1 pM. The trimeric myosin-bound phos- 
phatase was also inhibited by crPSF (Fig. 2B). This PPl prep- 
aration is Co’+-dependent [21]. It is interesting that the pre- 
sence of the two non-catalytic subunits did not block 
inhibition. The recombinant full-length PSF also inhibited 
the activity of rPP18. However, its effectiveness as an inhibitor 
was reduced compared to the crPSF fragment and in the 
presence of Co’+ the ICse was about 3 uM. 
Basic kinetic parameters were estimated from a double-re- 
ciprocal plot of v versus substrate (light chain) for rPP18 in 
the absence and presence of 1.8 pM crPSF fragment in the 
absence of Co’+. The major effect was on V, and this was 
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reduced from 0.84 f 0.06 to 0.4 + 0.01 nmol/min per mg pro- 
tein by addition of crPSF. K,,, values changed slightly from 
1.2f0.3 PM (control) to 2.2fO.S PM. 
Inhibition of PPl by inhibitors 1 and 2 and DARPP-32 
[21,23] occurs in the nanomolar range and it is therefore un- 
likely that the unmodified form of PSF functions as an in vivo 
inhibitor. In this context, it should be noted that the non- 
phosphorylated DARPP-32 inhibited PPlc with an TC50 about 
1 AM [24]. It is not known whether the properties of PSF are 
al I ered by post-translational modification, but a phosphory- 
la ed form of PSF has been detected in HeLa nuclear extracts 
(Patton, J.G., unpublished observations). 
The intent of the phosphatase assays was to confirm the 
results of the two-hybrid screen and to demonstrate by an 
indlependent method binding of PSF fragment and PPl. 
T:ds has been shown both for recombinant PPlc and for 
n;, tive PPl 
3. 1. Overlay with PPI catalytic subunit 
A second method to confirm binding of crPSF fragment 
al d PPlc was an overlay procedure using rPPl& Binding of 
rI’P16 was detected with the crPSF fragment and with the N- 
telminal fragment of the 130 kDa phosphatase subunit [19]. 
T’le latter served as a positive control. 
kDa 
205 - 
116- 
97.4- 
66- 
45- 
29- 
12345678 
Fig. 3. Overlay binding assay and SDS-PAGE patterns. (A) Lanes: 
1. crPSF fragment (4 pg); 2, bovine serum albumin (4 pg); 3, rN130 
(4 pg). (B) Lanes: 1,8, molecular weight markers; 2,3, bacterial 
hcmogenates before and after induction of crPSF fragment, respec- 
timely; 4, crPSF fragment; $6, C- and N-terminal peptides of 
crPSF fragment, respectively; 7, thrombin digest of crPSF fragment. 
P(&ion of parent crPSF indicated by arrow. 
A 
E 120 
0.01 0.1 1 10 100 
crPSF and Peptides (PM) 
Fig. 4. Effect of crPSF fragment and DTNB-CN cleavage products 
on gizzard PPlc. Parent crPSF fragment (0); C-terminal peptide 
(m); N-terminal peptide plus residual crPSF fragment, 11 :l molar 
ratio (0). Assay conditions given in Fig. 2, except that additional 
imidazole added with the N-terminal peptide was accounted for in 
controls. Data are means + S.E.M. (n = 4). 
3.4. Cleavage of the rPSFfragment 
In order to localize the binding site with a shorter sequence, 
various methods of cleavage were investigated. Limited pro- 
teolysis of rPSF fragment with a-chymotrypsin, trypsin and 
thermolysin resulted in loss of binding (as judged by inhibi- 
tion assays). Cleavage with thrombin at a site near the C- 
terminus generated a peptide of 29.7 kDa (Fig. 3) that re- 
tained inhibitory activity, but was only slightly smaller than 
the parent molecule. 
Non-proteolytic cleavage at the single C residue by DTNB- 
CN was investigated. Two peptides were generated of 13.4 
and 19.5 kDa (Fig. 3) corresponding to N-terminal and C- 
terminal fragments, respectively. The two peptides were sepa- 
rated and assayed for inhibition of phosphatase activity (Fig. 
4). The smaller N-terminal peptide retained the inhibitory 
effect. This peptide is composed of residues 349430 of the 
human PSF [ 131 plus the hexahistidine tag. It is known from 
other constructs [12] that the hexahistidine tag itself is not 
inhibitory. 
Patton et al. [13] showed that two isoforms of PSF exist, 
differing at the C-terminal end (after residue 662). Thus, both 
isoforms would contain the inhibitory sequence. Comparison 
of this sequence with other PPl inhibitors (inhibitors 1 and 2 
and DARPP-32) and the PPl-binding proteins, L5 [12] did 
not reveal a common motif indicative of a PPlc-binding se- 
quence. 
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